Novel lentiviral vectors displaying "early-acting cytokines" selectively promote survival and transduction of NOD/SCID repopulating human hematopoietic stem cells
- PMID: 16076865
- DOI: 10.1182/blood-2004-12-4736
Novel lentiviral vectors displaying "early-acting cytokines" selectively promote survival and transduction of NOD/SCID repopulating human hematopoietic stem cells
Abstract
A major limitation of current lentiviral vectors (LVs) is their inability to govern efficient gene transfer into quiescent cells, such as human CD34(+) cells, that reside in the G(0) phase of the cell cycle and that are highly enriched in hematopoietic stem cells. This hampers their application for gene therapy of hematopoietic cells. Here, we designed novel LVs that overcome this restriction by displaying "early-acting cytokines" on their surface. Display of thrombopoietin, stem cell factor, or both cytokines on the LV surface allowed efficient gene delivery into quiescent cord blood CD34(+) cells. Moreover, these surface-engineered LVs preferentially transduced and promoted survival of resting CD34(+) cells rather than cycling cells. Finally, and most importantly, these novel LVs allowed superior gene transfer in the most immature CD34(+) cells as compared to conventional LVs, even when the latter vectors were used to transduce cells in the presence of recombinant cytokines. This was demonstrated by their capacity to promote selective transduction of CD34(+) cell in in vitro derived long-term culture-initiating cell (LTC-IC) colonies and of long-term NOD/SCID repopulating cells (SRCs) in vivo.
Similar articles
-
Production of lentiviruses displaying ''early-acting'' cytokines for selective gene transfer into hematopoietic stem cells.Methods Mol Biol. 2008;434:99-112. doi: 10.1007/978-1-60327-248-3_7. Methods Mol Biol. 2008. PMID: 18470641
-
In vivo gene delivery into hCD34+ cells in a humanized mouse model.Methods Mol Biol. 2011;737:367-90. doi: 10.1007/978-1-61779-095-9_15. Methods Mol Biol. 2011. PMID: 21590405
-
Cytokines, including stem cell factor alone, enhance lentiviral transduction in nondividing human LTCIC and NOD/SCID repopulating cells.Mol Ther. 2003 Mar;7(3):325-33. doi: 10.1016/s1525-0016(03)00005-4. Mol Ther. 2003. PMID: 12668128
-
Cellular innate immunity and restriction of viral infection: implications for lentiviral gene therapy in human hematopoietic cells.Hum Gene Ther. 2015 Apr;26(4):201-9. doi: 10.1089/hum.2015.036. Epub 2015 Apr 13. Hum Gene Ther. 2015. PMID: 25808164 Review.
-
Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy.Mol Ther. 2010 Oct;18(10):1748-57. doi: 10.1038/mt.2010.178. Epub 2010 Aug 24. Mol Ther. 2010. PMID: 20736930 Free PMC article. Review.
Cited by
-
Prolonged adherence of human immunodeficiency virus-derived vector particles to hematopoietic target cells leads to secondary transduction in vitro and in vivo.J Virol. 2007 Jan;81(2):639-49. doi: 10.1128/JVI.01089-06. Epub 2006 Oct 11. J Virol. 2007. PMID: 17035328 Free PMC article.
-
Towards Physiologically and Tightly Regulated Vectored Antibody Therapies.Cancers (Basel). 2020 Apr 13;12(4):962. doi: 10.3390/cancers12040962. Cancers (Basel). 2020. PMID: 32295072 Free PMC article. Review.
-
The Ongoing Challenge of Hematopoietic Stem Cell-Based Gene Therapy for β-Thalassemia.Stem Cells Int. 2011;2011:987980. doi: 10.4061/2011/987980. Epub 2011 Nov 13. Stem Cells Int. 2011. PMID: 22190966 Free PMC article.
-
Viral vectors: from virology to transgene expression.Br J Pharmacol. 2009 May;157(2):153-65. doi: 10.1038/bjp.2008.349. Br J Pharmacol. 2009. PMID: 18776913 Free PMC article. Review.
-
Protein transduction from retroviral Gag precursors.Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7805-10. doi: 10.1073/pnas.0914517107. Epub 2010 Apr 12. Proc Natl Acad Sci U S A. 2010. PMID: 20385817 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
